Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care

References

• Katznelson L, Atkinson J, Cook D, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocrine Pract. 2011;17(suppl 4):1–44.
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189–3202.
   PubMed Web of Science ®Google Scholar
• Vilar L, Freitas Vilar C, Lyra R, et al. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22–32.
   PubMed Web of Science ®Google Scholar
• Lesen E, Granfeldt D, Houchard A, et al. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017;176(2):203–212.
   PubMed Web of Science ®Google Scholar
• Ritvonen E, Löyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocrine Related Cancer. 2016;23(6):469–480.
   PubMed Web of Science ®Google Scholar
• Lavrentaki A, Paluzzi A, Wass JAH, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9.
   PubMed Web of Science ®Google Scholar
• Placzek H, Xu Y, Mu Y, et al. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J Manag Care Spec Pharm. 2015;21(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558–2573.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–248.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61–67.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER, Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Laws ER, Jane JA. Jr. Neurosurgical approach to treating pituitary adenomas. Growth Horm IGF Res. 2005;15(Supplement A):S36–S41.
   PubMed Web of Science ®Google Scholar
• Gurel MH, Han Y, Stevens AL., et al. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC Pharmacol Toxicol. 2017;18(1):22
   PubMed Web of Science ®Google Scholar
• Caputo M, Ucciero A, Mele C, et al. Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy. J Endocrinol Invest. 2019;42(4):397–402.
   PubMed Web of Science ®Google Scholar
• Chuang C-C, Bhurke S, Chen S-Y, et al. Treatment patterns and economic burden in patients treated for acromegaly in the USA. Drugs – Real World Outcomes. 2015;2(3):299–309.
   PubMedGoogle Scholar
• Burton T, Le Nestour E, Neary M, et al. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19(3):262–267.
   PubMed Web of Science ®Google Scholar
• Broder MS, Chang E, Reddy SR, et al. An approach to using data mining to support early identification of acromegaly. Endocr Pract. 2017;23(4):422–431.
   PubMed Web of Science ®Google Scholar
• Yuen KCJ, Munoz KA, Brook RA, et al. Acromegaly significantly impacts employees’ health benefit costs and increases work absenteeism (abstract). Jesoci. 2020;4(Suppl):A189–A190.
   Google Scholar
• Rudmik L, Drummond M. Health economic evaluation: important principles and methodology. Laryngoscope. 2013;123(6):1341–1347.
   PubMed Web of Science ®Google Scholar
• Porto LB, Zimmermann IR, Naves LA. Economics of acromegaly treatment in Brazil: a budget impact analysis of pituitary surgery compared with long-term octreotide LAR. Pharmacoecon Open. 2019;3(2):247–254.
   PubMed Web of Science ®Google Scholar
• Kimmell KT, Weil RJ, Marko NF. Multi-modal management of acromegaly: a value perspective. Pituitary. 2015;18(5):658–665.
   PubMed Web of Science ®Google Scholar
• ICD9data.com [Internet]. ICD-9-CM Diagnosis Code 253.0: Acromegaly and gigantism. 2014. [cited 2020 Feb 22]. Available from: http://www.icd9data.com/2014/Volume1/240-279/249-259/253/253.0.htm.
   Google Scholar
• ICD10data.com [Internet]. ICD-10-CM Diagnosis Code E22.0: acromegaly and pituitary gigantism. 2020. [cited 2020 Feb 22]. https://www.icd10data.com/ICD10CM/Codes/E00-E89/E20-E35/E22-/E22.0#:∼:text=Acromegaly%20and%20pituitary%20gigantism,-2016%202017%202018&text=Billable%2FSpecific%20Code-,E22.,effective%20on%20October%201%2C%202020.
   Google Scholar
• Brook RA, Kleinman NL, Choung RS, et al. Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population. Dig Dis Sci. 2012;57(1):109–118.
   PubMed Web of Science ®Google Scholar
• Brook RA, Kleinman NL, Patel S, et al. United States comparative costs and absenteeism of diabetic ophthalmic conditions. Postgrad Med. 2015;127(5):455–462.
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Consumer Price Index. 2019. [cited 2019 December 1]. https://www.bls.gov/cpi/.
   Google Scholar
• Broder MS, Neary MP, Chang E, et al. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17(4):333–341.
   PubMed Web of Science ®Google Scholar
• Ebrahimi F, Widmer A, Wagner U, et al. Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients. Eur J Endocrinol. 2019;181(6):701–709.
   PubMed Web of Science ®Google Scholar
• Yedinak C, Hameed N, Gassner M, et al. Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study. Pituitary. 2015;18(5):701–709.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Brue T, et al. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol. 2020;182(6):583.
   PubMed Web of Science ®Google Scholar
• Colao A, Grasso LFS, Di Cera M, et al. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. J Endocrinol Invest. 2020;43(4):529–538.
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Broder MS, Cherepanov D, et al. The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord. 2017;17(1):15.
   PubMed Web of Science ®Google Scholar
• Johnson EK, Nelson CP. Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013;190(1):17–18.
   PubMed Web of Science ®Google Scholar
• Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7 Suppl 1):S51–S55.
   PubMed Web of Science ®Google Scholar